Odonate Therapeutics, Inc. (ODTC) Research

Odonate Therapeutics, Inc., a pharmaceutical company established in 2013 and headquartered in New York, New York, is dedicated to creating treatments for cancer. Its primary therapeutic in development is tesetaxel, an orally administered chemotherapy drug. This agent is currently undergoing a Phase III clinical study for its application in patients suffering from metastatic breast cancer.

Market snapshot

Symbol
ODTC
Price
$22,005
Day change
+29.44%
Market cap
$8.0B
P/E ratio
3227.30x
52-week range
22005-358000
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 1 month

Peer companies

  • Eisai Co., Ltd. (ESALY)
  • Gelesis Holdings, Inc. (GLSHQ)
  • Generex Biotechnology Corporation (GNBT)
  • Humanigen, Inc. (HGENQ)
  • TuHURA Biosciences, Inc. (HURA)
  • Immune Therapeutics, Inc. (IMUN)
  • IMV Inc. (IMVIQ)
  • JD Health International Inc. (JDHIY)

Open Odonate Therapeutics, Inc. (ODTC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.